File(s) not publicly available

The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: A study protocol for a randomized controlled non-inferiority trial

journal contribution
posted on 04.09.2019, 00:00 by D Thomas, M Farrell, H McRobbie, P Tutka, D Petrie, R West, M Siahpush, C Gartner, N Walker, CP Mendelsohn
Background and aims: Smoking cessation medications are effective, but often underutilized because of costs and side effects. Cytisine is a plant-based smoking cessation medication with more than 50 years of use in central and eastern Europe. While cytisine has been found to be well-tolerated and more effective than nicotine replacement therapy, direct comparisons with varenicline have not been conducted. This study evaluates the effectiveness, safety and cost-effectiveness of cytisine compared with varenicline. Design: Two-arm, parallel group, randomized, non-inferiority trial, with allocation concealment and blinded outcome assessment. Setting: Australian population-based study. Participants: Adult daily smokers (n = 1266) interested in quitting will be recruited through advertisements and Quitline telephone-based cessation support services. Intervention and comparator: Eligible participants will be randomized (1 : 1 ratio) to receive either cytisine capsules (25-day supply) or varenicline tablets (12-week supply), prescribed in accordance with the manufacturer's recommended dosing regimen. The medication will be mailed to each participant's nominated residential address. All participants will also be offered standard Quitline behavioural support (up to six 10–12-minute sessions). Measurements: Assessments will be undertaken by telephone at baseline, 4 and 7 months post-randomization. Participants will also be contacted twice (2 and 4 weeks post-randomization) to ascertain adverse events, treatment adherence and smoking status. The primary outcome will be self-reported 6-month continuous abstinence from smoking, verified by carbon monoxide at 7-month follow-up. We will also evaluate the relative safety and cost-effectiveness of cytisine compared with varenicline. Secondary outcomes will include self-reported continuous and 7-day point prevalence abstinence and cigarette consumption at each follow-up interview. Comments: If cytisine is as effective as varenicline, its lower cost and natural plant-based composition may make it an acceptable and affordable smoking cessation medication that could save millions of lives world-wide. © 2018 Society for the Study of Addiction

Funding

Category 3 - Industry and Other Research Income

History

Volume

114

Issue

5

Start Page

923

End Page

933

Number of Pages

11

eISSN

1360-0443

ISSN

0965-2140

Publisher

Wiley-Blackwell Publishing, UK

Peer Reviewed

Yes

Open Access

No

Acceptance Date

17/12/2018

External Author Affiliations

University of Tasmania; University of Auckland; University of Auckland; University of Queensland; University of Nebraska Medical Center, USA; University of New South Wales; Monash University; University College London

Author Research Institute

Centre for Indigenous Health Equity Research

Era Eligible

Yes

Journal

Addiction

Usage metrics

CQUniversity

Exports